

## **United States Antibody Drug Conjugates Contract Manufacturing Market Forecast 2024-2032**

Market Report | 2024-05-20 | 128 pages | Inkwood Research

### **AVAILABLE LICENSES:**

- Single User Price \$1100.00
- Global Site License \$1500.00

### **Report description:**

#### **KEY FINDINGS**

The United States antibody drug conjugates contract manufacturing market is approximated to develop at a CAGR of 12.29% during the forecast period 2024-2032. Different enablers elevate market growth, the rising demand for targeted therapies, the growing inclination towards contract manufacturing companies as an economical choice, the surging global cancer incidence, and advancements in drug conjugation technologies.

#### **MARKET INSIGHTS**

The United States antibody drug conjugates contract manufacturing market is a significant sphere within the pharmaceutical and biotechnology industries. This market specializes in the development and production of ADCs, which are a type of targeted cancer therapy. ADCs combine antibodies that specifically target cancer cells with potent drugs, delivering the drug directly to cancer cells while minimizing damage to healthy cells. This precision makes ADCs highly effective in treating certain types of cancer, driving the demand for contract manufacturing services to produce these innovative therapies.

The increasing prevalence of cancer is a key factor pushing the growth of the ADC contract manufacturing market in the United States. With cancer rates on the rise and the need for more effective and targeted treatments, the demand for ADCs continues to grow. This trend is particularly notable in areas such as oncology, where ADCs offer promising solutions for patients with challenging-to-treat cancers.

Further, the United States is a center for innovation and investment in the biopharmaceutical sector, including ADC development and manufacturing. The presence of leading pharmaceutical companies, contract manufacturing organizations (CMOs), and research institutions fosters a conducive environment for the growth of the market. Additionally, regulatory agencies play a crucial role in ensuring compliance and quality standards supporting market development.

#### **COMPETITIVE INSIGHTS**

Some of the major companies in the United States antibody drug conjugates contract manufacturing market include AbbVie Inc (AbbVie Contract Manufacturing), Merck KGaA, Catalent Inc, etc.

Our report offerings include:

- Explore key findings of the overall market

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation caters to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- The competitive landscape is the theoretical explanation of the key companies based on factors such as market share.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

## **Table of Contents:**

### TABLE OF CONTENTS

#### 1. RESEARCH SCOPE & METHODOLOGY

##### 1.1. STUDY OBJECTIVES

##### 1.2. METHODOLOGY

##### 1.3. ASSUMPTIONS & LIMITATIONS

#### 2. EXECUTIVE SUMMARY

##### 2.1. MARKET SIZE & ESTIMATES

##### 2.2. COUNTRY SNAPSHOT

##### 2.3. COUNTRY ANALYSIS

##### 2.4. SCOPE OF STUDY

##### 2.5. CRISIS SCENARIO ANALYSIS

##### 2.6. MAJOR MARKET FINDINGS

###### 2.6.1. INCREASING COLLABORATION BETWEEN KEY CONTRACT MANUFACTURERS (CMOS)

###### 2.6.2. CHALLENGES IN NAVIGATING COMPLEX REGULATORY REQUIREMENTS

#### 3. MARKET DYNAMICS

##### 3.1. KEY DRIVERS

###### 3.1.1. RISING DEMAND FOR TARGETED THERAPIES

###### 3.1.2. GROWING INCLINATION TOWARDS CONTRACT MANUFACTURING COMPANIES AS AN ECONOMICAL CHOICE

###### 3.1.3. SURGING GLOBAL CANCER INCIDENCE

###### 3.1.4. ADVANCEMENTS IN DRUG CONJUGATION TECHNOLOGIES

##### 3.2. KEY RESTRAINTS

###### 3.2.1. HIGH COST OF ADC (ANTIBODY DRUG CONJUGATES) DEVELOPMENT AND MANUFACTURING

###### 3.2.2. INCREASING COMPETITION FROM BIOSIMILAR ADC (ANTIBODY DRUG CONJUGATES) AND GENERIC DRUGS

###### 3.2.3. STRINGENT REGULATORY REQUIREMENTS

#### 4. KEY ANALYTICS

##### 4.1. KEY MARKET TRENDS

###### 4.1.1. RISING DEMAND FOR ADCS

###### 4.1.2. GROWING FOCUS ON ADC QUALITY AND REGULATORY COMPLIANCE

##### 4.2. PESTLE ANALYSIS

###### 4.2.1. POLITICAL

###### 4.2.2. ECONOMICAL

###### 4.2.3. SOCIAL

###### 4.2.4. TECHNOLOGICAL

###### 4.2.5. LEGAL

###### 4.2.6. ENVIRONMENTAL

##### 4.3. PORTER'S FIVE FORCES ANALYSIS

###### 4.3.1. BUYERS POWER

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
- 4.4. GROWTH PROSPECT MAPPING
- 4.4.1. GROWTH PROSPECT MAPPING FOR UNITED STATES
- 4.5. MARKET CONCENTRATION ANALYSIS
- 4.6. KEY BUYING CRITERIA
- 4.6.1. EXPERTISE AND EXPERIENCE
- 4.6.2. MANUFACTURING CAPACITY
- 4.6.3. REGULATORY COMPLIANCE
- 4.6.4. QUALITY CONTROL
- 4.6.5. COST
- 4.7. REGULATORY FRAMEWORK
- 5. MARKET BY PHASE
- 5.1. CLINICAL PHASE
- 5.1.1. MARKET FORECAST FIGURE
- 5.1.2. SEGMENT ANALYSIS
- 5.2. COMMERCIAL PHASE
- 5.2.1. MARKET FORECAST FIGURE
- 5.2.2. SEGMENT ANALYSIS
- 6. MARKET BY LINKER
- 6.1. CLEAVABLE LINKERS
- 6.1.1. MARKET FORECAST FIGURE
- 6.1.2. SEGMENT ANALYSIS
- 6.2. NON-CLEAVABLE LINKERS
- 6.2.1. MARKET FORECAST FIGURE
- 6.2.2. SEGMENT ANALYSIS
- 7. MARKET BY CONDITION
- 7.1. MYELOMA
- 7.1.1. MARKET FORECAST FIGURE
- 7.1.2. SEGMENT ANALYSIS
- 7.2. LYMPHOMA
- 7.2.1. MARKET FORECAST FIGURE
- 7.2.2. SEGMENT ANALYSIS
- 7.3. BREAST CANCER
- 7.3.1. MARKET FORECAST FIGURE
- 7.3.2. SEGMENT ANALYSIS
- 7.4. OTHER CONDITIONS
- 7.4.1. MARKET FORECAST FIGURE
- 7.4.2. SEGMENT ANALYSIS
- 8. COMPETITIVE LANDSCAPE
- 8.1. KEY STRATEGIC DEVELOPMENTS
- 8.1.1. MERGERS & ACQUISITIONS
- 8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 8.1.3. PARTNERSHIPS & AGREEMENTS
- 8.2. COMPANY PROFILES

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

8.2.1. ABBVIE INC (ABBVIE CONTRACT MANUFACTURING)

8.2.1.1. COMPANY OVERVIEW

8.2.1.2. SERVICES LIST

8.2.1.3. STRENGTHS & CHALLENGES

8.2.2. CAMBREX CORPORATION

8.2.2.1. COMPANY OVERVIEW

8.2.2.2. SERVICES LIST

8.2.3. CATALENT INC

8.2.3.1. COMPANY OVERVIEW

8.2.3.2. SERVICES LIST

8.2.3.3. STRENGTHS & CHALLENGES

8.2.4. MERCK KGAA

8.2.4.1. COMPANY OVERVIEW

8.2.4.2. SERVICES LIST

8.2.4.3. STRENGTHS & CHALLENGES

8.2.5. PIRAMAL PHARMA SOLUTIONS

8.2.5.1. COMPANY OVERVIEW

8.2.5.2. SERVICES LIST

8.2.5.3. STRENGTHS & CHALLENGES

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## United States Antibody Drug Conjugates Contract Manufacturing Market Forecast 2024-2032

Market Report | 2024-05-20 | 128 pages | Inkwood Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User Price	\$1100.00
	Global Site License	\$1500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-09"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com